Trials / Withdrawn
WithdrawnNCT02070887
Inhibiting COMT in Parkinson's Disease
Inhibiting COMT in Parkinson's Disease A Monocenter, Observational, Rater-blinded Trial of Entacapone in Parkinson's Disease
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Christian Baumann · Academic / Other
- Sex
- All
- Age
- 60 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The overall aim of this observational study is to investigate the impact of COMT inhibition on homocysteine metabolism, vascular physiology and correlates of neurodegeneration in PD patients with certain COMT genotype. It is designed to evaluate effect size of Hcy lowering to secondary outcome parameters. Assessment of outcome parameters will be rater-blinded or computer-based.
Conditions
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-08-01
- Completion
- 2014-09-01
- First posted
- 2014-02-25
- Last updated
- 2021-01-25
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02070887. Inclusion in this directory is not an endorsement.